TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30737094

Group type: EXPERIMENTAL
Intervention: Video-based online training
Number of subjects: 131

Group type: COMPARATOR
Intervention: Delayed intervention comparison group
Number of subjects: 131
Study: 28004376

Group type: EXPERIMENTAL
Intervention: Dilmapimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28247686

Group type: EXPERIMENTAL
Intervention: Testosterone level
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Peak systolic velocity of blood flow in the capsular arteries of testes
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Testicular size
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Serum testosterone levels
Number of subjects: 131
Study: 23328847

Group type: EXPERIMENTAL
Intervention: Radio-frequency nerve ablation (RFNA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Radio-frequency nerve ablation (RFNA) after crossover from sham treatment
Number of subjects: 17
Study: 21299254

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 52

Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 52
Study: 19287286

Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 2.5 mg bevacizumab
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 52
Study: 16754351

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy with hyperthermia
Number of subjects: 137

Group type: COMPARATOR
Intervention: Neoadjuvant radiochemotherapy without hyperthermia
Number of subjects: 137
Study: 14969649

Group type: EXPERIMENTAL
Intervention: Glyburide/metformin plus rosiglitazone (4 mg once daily)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Glyburide/metformin plus rosiglitazone
Number of subjects: 365

Group type: COMPARATOR
Intervention: Glyburide/metformin plus placebo
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Rosiglitazone-treated group
Number of subjects: 365
Study: 11515892

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Epsilon Aminocaproic Acid (EACA)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 9403284

Group type: EXPERIMENTAL
Intervention: Erythromycin 1 g b.i.d. for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dirithromycin 500 mg qd for 5 days
Number of subjects: 10
Study: 8144986

Group type: COMPARATOR
Intervention: Radiotherapy alone (4 Gy per fraction, three fractions per week to a total dose of 24 Gy)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with hyperthermia (same radiotherapy regimen, regional hyperthermia for 35‐60 min after irradiation, two sessions per week to a total of four sessions)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Group 2 (low)
Number of subjects: 49
Study: 2975806

Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: nortriptyline
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: desipramine
Number of subjects: 73

Group type: COMPARATOR
Intervention: zimelidine
Number of subjects: 73
Study: 31084381

Group type: EXPERIMENTAL
Intervention: Green tea extract (400 mg daily for 12 weeks)
Number of subjects: 20
Study: 28193771

Group type: EXPERIMENTAL
Intervention: Ceritinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 24180479

Group type: EXPERIMENTAL
Intervention: i.v. mitoxantrone (MTX), oral vinorelbine, or oral etoposide, together with oral prednisone
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 92
Study: 23242572

Group type: EXPERIMENTAL
Intervention: NR-INF-02 (500 mg twice daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (400 mg twice daily)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate (GS) (750 mg twice daily)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of NR-INF-02 and GS
Number of subjects: 120
Study: 21527870

Group type: EXPERIMENTAL
Intervention: Simulation-based training + audiovisual training (AV)
Number of subjects: 51

Group type: COMPARATOR
Intervention: AV only (Control)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Simulation-based training + AV
Number of subjects: 51
Study: 18083691

Group type: EXPERIMENTAL
Intervention: ILF (irinotecan 150 mg/m², leucovorin 20 mg/m², 5-FU 1000 mg/m² on days 1 and 2)
Number of subjects: 91

Group type: COMPARATOR
Intervention: PILF (ILF plus cisplatin 30 mg/m² on day 2)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: ILF
Number of subjects: 91

Group type: COMPARATOR
Intervention: PILF
Number of subjects: 91
Study: 16939360

Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 17

Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 17
Study: 12660333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Benazepril (20 mg once daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg once daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dual blockade (20 mg benazepril + 80 mg valsartan)
Number of subjects: 20
Study: 10971305

Group type: EXPERIMENTAL
Intervention: Stevioside (250 mg) thrice daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 8832991

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg equivalent)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Oxipurinol sodium
Number of subjects: 99

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 99
Study: 1449107

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 540 mg/m2 with folinic acid (FA) 500 mg/m2 and rhGM-CSF
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 450 mg/m2 with folinic acid (FA) 500 mg/m2 and rhGM-CSF
Number of subjects: 15
Study: 6150276

Group type: EXPERIMENTAL
Intervention: 75 mg or 150 mg kanamycin plus gentamicin eye ointment (for 3 days)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Single-dose kanamycin with saline eye washes (for 3 days)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 150 mg kanamycin plus chloramphenicol eye drops
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Postgonococcal conjunctivitis
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal infection with N gonorrhoeae
Number of subjects: 117
Study: 30371557

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: BISAD, Checklist of Nonverbal Pain Indicators, Algoplus
Number of subjects: 0
Study: 28443675

Group type: EXPERIMENTAL
Intervention: Palmar proximal injection approach
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Palmar distal injection approach
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Webspace injection approach
Number of subjects: 38
Study: 26676838

Group type: EXPERIMENTAL
Intervention: O2-O3 intradiscal injection
Number of subjects: 517
Study: 24832476

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Mind Fitness Training (MMFT)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Training-as-usual control condition
Number of subjects: 281
Study: 21884857

Group type: EXPERIMENTAL
Intervention: Berlin Heart EXCOR Pediatric ventricular assist device (VAD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Extracorporeal membrane oxygenation (control)
Number of subjects: 48
Study: 19012050

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated estrogen (CE) + 2.5 mg medroxyprogesterone acetate (MPA)/day
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone/day
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no hormone replacement therapy)
Number of subjects: 95
Study: 16918861

Group type: EXPERIMENTAL
Intervention: Comprehensive school-based asthma program facilitated by trained school nurses and PCP training.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified).
Number of subjects: 0
Study: 14725828

Group type: EXPERIMENTAL
Intervention: Specialist nurse home visit
Number of subjects: 174

Group type: COMPARATOR
Intervention: Consultant clinic review
Number of subjects: 174
Study: 11505044

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (0, 50, 125, 375, and 500 microg/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 9023459

Group type: EXPERIMENTAL
Intervention: Inulin (7 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oligofructose (17 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (7 g of sucrose)
Number of subjects: 0
Study: 8420063

Group type: EXPERIMENTAL
Intervention: OKT3 plus azathioprine and steroids for 14 days with delayed addition of cyclosporine on day 11
Number of subjects: 215

Group type: COMPARATOR
Intervention: Conventional immunosuppression (steroids, azathioprine, and cyclosporine)
Number of subjects: 215
Study: 3106632

Group type: EXPERIMENTAL
Intervention: 125 mg/day D‐penicillamine
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: 500 mg D‐penicillamine
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (D‐penicillamine trial)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate (GSTM)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Auranofin (AF)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (GSTM/AF trial)
Number of subjects: 174
Study: 788855

Group type: EXPERIMENTAL
Intervention: Graded compression using specially designed elastic stockings
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no graded compression)
Number of subjects: 98
Study: 31937181

Group type: EXPERIMENTAL
Intervention: Beta neurofeedback training (12-22 Hz) for 20 sessions of 30 minutes each on the Cz site
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no neurofeedback training)
Number of subjects: 0
Study: 31237134

Group type: EXPERIMENTAL
Intervention: OM3-FAs 4,000 mg plus atorvastatin 20 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg plus placebo
Number of subjects: 200
Study: 31030590

Group type: EXPERIMENTAL
Intervention: Prophylactic HPV vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28039060

Group type: EXPERIMENTAL
Intervention: Prophylactic oral calcium supplementation
Number of subjects: 106

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 106
Study: 25365032

Group type: EXPERIMENTAL
Intervention: Caffeinated carbohydrate gel (CC) - 21.6 g carbohydrate, 100 mg caffeine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Carbohydrate-only placebo gel (CP) - 21.6 g carbohydrate, 0 mg caffeine
Number of subjects: 13
Study: 23866306

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg
Number of subjects: 808

Group type: COMPARATOR
Intervention: doubling the baseline statin dose (simvastatin 40 mg or atorvastatin 20 mg)
Number of subjects: 808

Group type: COMPARATOR
Intervention: rosuvastatin 10 mg
Number of subjects: 808
Study: 21894686

Group type: EXPERIMENTAL
Intervention: Meridian-harmonization group (group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Zang-organ regulation group (group B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Meridian-harmonization and zang-organ regulation group (group C)
Number of subjects: 150
Study: 19125756

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (120,000 IU each; three doses, administered fortnightly)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study: 17291720

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CrPic), 200 microg Cr/d
Number of subjects: 83

Group type: COMPARATOR
Intervention: Picolinic acid (1720 microg)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 15673989

Group type: EXPERIMENTAL
Intervention: SP6 acupressure
Number of subjects: 75

Group type: COMPARATOR
Intervention: SP6 touch control
Number of subjects: 75
Study: 11697576

Group type: EXPERIMENTAL
Intervention: Clozapine (200-600 mg/day)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Olanzapine (10-30 mg/day)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Risperidone (8-16 mg/day)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Haloperidol (10-40 mg/day)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Sulpiride (600-1600 mg/day)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Drug-free state
Number of subjects: 114

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 114
Study: 9215169

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 8426714

Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam with nitrous oxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam (mean dose = 19.3 mg)
Number of subjects: 0
Study: 3618574

Group type: EXPERIMENTAL
Intervention: Phenobarbital for five days
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 238
Study: 29742145

Group type: EXPERIMENTAL
Intervention: Unilateral backpack (UB) carrying (12.5% body weight)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Unilateral backpack (UB) carrying
Number of subjects: 9

Group type: COMPARATOR
Intervention: No backpack (NB)
Number of subjects: 9
Study: 26468897

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 877

Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 877
Study: 25917574

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20mg
Number of subjects: 521

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521
Study: 23596051

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (Gb) treatment
Number of subjects: 190

Group type: COMPARATOR
Intervention: Cognitively normal subjects
Number of subjects: 190

Group type: COMPARATOR
Intervention: Mild cognitive impairment (MCI) subjects
Number of subjects: 190

Group type: COMPARATOR
Intervention: APOE*4 allele presence
Number of subjects: 190

Group type: COMPARATOR
Intervention: Cognitively normal and MCI subjects combined
Number of subjects: 190

Group type: COMPARATOR
Intervention: Long-term exposure to Gb
Number of subjects: 190
Study: 20875183

Group type: EXPERIMENTAL
Intervention: 12.5% protein preload (1675 kJ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25% protein preload (1675 kJ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50% protein preload (1675 kJ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% protein preload (1047 kJ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20% protein preload (1047 kJ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40% protein preload (1047 kJ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (flavoured water preload)
Number of subjects: 0
Study: 18254761

Group type: EXPERIMENTAL
Intervention: IN morphine 3.75 mg, 7.5 mg, 15 mg, or 30 mg
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: IV morphine 7.5 mg
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: IN morphine 7.5 mg
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: IN morphine 15 mg
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: IV morphine
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 16689066

Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide whitening strip
Number of subjects: 48

Group type: COMPARATOR
Intervention: 6.5% hydrogen peroxide whitening strip
Number of subjects: 48
Study: 15301625

Group type: EXPERIMENTAL
Intervention: Participants who lost a competition to atypical men or women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants who lost a competition to typical men or women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender deviants fearing backlash
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceivers who sabotaged deviants (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deviants who hid their atypicality (Experiment 3)
Number of subjects: 0
Study: 11220430

Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg(‐1) of oral transmucosal midazolam mixed with strawberry syrup
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo group received plain syrup 0.08 ml x kg(‐1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg(‐1) of oral transmucosal midazolam
Number of subjects: 44
Study: 9283123

Group type: EXPERIMENTAL
Intervention: Relactation with motivation, support, and repeated suckling
Number of subjects: 50

Group type: COMPARATOR
Intervention: Relactation with motivation, support, repeated suckling, and metoclopramide (Group II)
Number of subjects: 50
Study: 8193524

Group type: EXPERIMENTAL
Intervention: Matrix controlled clonidine transdermal (C‐TD) system
Number of subjects: 905

Group type: COMPARATOR
Intervention: Membrane controlled clonidine system (C‐TTS)
Number of subjects: 905
Study: 2419009

Group type: EXPERIMENTAL
Intervention: Recombinant human tissue-type plasminogen activator (rt-PA) 0.75 mg/kg over 90 min
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Streptokinase 1,500,000 IU over 60 min
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 29451020

Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib, ceritinib, and alectinib (previous treatments)
Number of subjects: 0
Study: 29894611

Group type: EXPERIMENTAL
Intervention: FiO₂ 100%
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: FiO₂ 70%
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: FiO₂ 50%
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Prognostic model based on seven bedside tests
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: FiO₂ 50-60%
Number of subjects: 71
Study: 23866092

Group type: EXPERIMENTAL
Intervention: Integrative acupoint stimulation (IAS) - auricular acupressure combined with transcutaneous electric acupoint stimulation (TEAS) at the true acupoint
Number of subjects: 135

Group type: COMPARATOR
Intervention: Sham group - acupoint stimulation at a sham acupoint or without embedding seeds and pressure
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group - no IAS intervention
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Integrative acupoint stimulation (IAS)
Number of subjects: 135
Study: 22396387

Group type: EXPERIMENTAL
Intervention: Active conservative treatment for urinary incontinence (UI)
Number of subjects: 853
Study: 19628566

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 564

Group type: COMPARATOR
Intervention: Control (no tamoxifen)
Number of subjects: 564
Study: 18469351

Group type: EXPERIMENTAL
Intervention: Deferasirox (ICL670)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 49
Study: 16882049

Group type: EXPERIMENTAL
Intervention: Double J 6-Fr polyurethane stents placed for 3 weeks (Group A)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-stented patients (Group B)
Number of subjects: 56
Study: 12942573

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipenem or Cefepime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipenem or Cefepime with vancomycin or amikacin
Number of subjects: 0
Study: 10381164

Group type: EXPERIMENTAL
Intervention: Cranial Electrical Stimulation (CES) for 20 minutes
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 52
Study: 8896856

Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP[+])
Number of subjects: 40

Group type: COMPARATOR
Intervention: No cricoid pressure (CP[-])
Number of subjects: 40
Study: 1653711

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure mask physiotherapy (PEP)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Forced expiration technique combined with postural drainage (FET/PD)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control
Number of subjects: 7
Study: 6500759

Group type: EXPERIMENTAL
Intervention: Aminophylline micropellets (Euphyllin CR 350)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theophylline micropellets
Number of subjects: 12
Study: 31248863

Group type: EXPERIMENTAL
Intervention: dT1
Number of subjects: 123

Group type: COMPARATOR
Intervention: 2D manual delineation
Number of subjects: 123
Study: 30081948

Group type: EXPERIMENTAL
Intervention: Group I: six sessions, three exercises, two sets; includes additional perturbations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group II: six sessions, two exercises, two sets; includes additional perturbations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group III: six sessions, one exercise, three sets; includes additional perturbations.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group: standardized exercise program of four sensorimotor exercises (three sets of 10 repetitions) in each of six training sessions (30 min duration) over 3 weeks.
Number of subjects: 0
Study: 27033959

Group type: EXPERIMENTAL
Intervention: 3D power Doppler (3DPD) angiography with five different machine settings
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 3D power Doppler (3DPD) angiography
Number of subjects: 112
Study: 24274799

Group type: EXPERIMENTAL
Intervention: Positive expectation group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Negative expectation group
Number of subjects: 60
Study: 22323351

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sedentary (AS)
Number of subjects: 16
Study: 20172565

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Shock wave lithotripsy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 94
Study: 17382108

Group type: EXPERIMENTAL
Intervention: Postnatal dexamethasone (DEX)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68